Moderna, Inc. $MRNA Shares Sold by Contravisory Investment Management Inc.

Contravisory Investment Management Inc. decreased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 37.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,050 shares of the company’s stock after selling 9,168 shares during the quarter. Contravisory Investment Management Inc.’s holdings in Moderna were worth $2,898,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. TD Waterhouse Canada Inc. lifted its holdings in shares of Moderna by 2.6% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock worth $246,000 after acquiring an additional 85 shares during the period. MassMutual Private Wealth & Trust FSB boosted its position in shares of Moderna by 8.8% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 1,976 shares of the company’s stock worth $381,000 after acquiring an additional 159 shares during the last quarter. Assetmark Inc. boosted its position in shares of Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after acquiring an additional 208 shares during the last quarter. Versant Capital Management Inc grew its holdings in Moderna by 13.8% in the third quarter. Versant Capital Management Inc now owns 2,491 shares of the company’s stock valued at $480,000 after purchasing an additional 302 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Moderna by 21.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,153 shares of the company’s stock valued at $63,000 after purchasing an additional 387 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MRNA. Wolfe Research raised shares of Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday, August 25th. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a research note on Wednesday, August 19th. Evercore boosted their price objective on shares of Moderna from $50.00 to $80.00 in a research note on Thursday, October 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. Finally, Singular Research raised Moderna to a “hold” rating in a research report on Wednesday, September 23rd. Seven research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $100.60.

Moderna Trading Up 1.2%

NASDAQ MRNA traded up $2.51 during mid-day trading on Tuesday, hitting $216.25. The company’s stock had a trading volume of 13,366,030 shares, compared to its average volume of 12,251,396. The firm has a market capitalization of $86.34 billion, a P/E ratio of -27.07 and a beta of 1.09. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $227.46. The stock’s fifty day simple moving average is $143.25 and its two-hundred day simple moving average is $86.30.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same period in the previous year, the firm earned ($2.13) earnings per share. Moderna’s revenue for the quarter was up 2.1% on a year-over-year basis. Research analysts expect that Moderna, Inc. will post -6.11 EPS for the current year.

Insider Activity

In related news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider owned 74,129 shares in the company, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 40,294 shares of the company’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the sale, the president directly owned 1,525,858 shares of the company’s stock, valued at approximately $219,921,913.54. This trade represents a 2.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 118,882 shares of company stock valued at $16,862,280. Company insiders own 10.80% of the company’s stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Investor enthusiasm has strengthened after reports of positive results for Moderna’s mRNA-based cancer vaccine. A planned NIH-backed initiative to accelerate personalized cancer-vaccine development could provide additional funding, visibility and partnership opportunities for the company’s oncology platform. Moderna’s Cancer Vaccine Breakthrough Drives Sharp Stock Rally
• Positive Sentiment: Moderna’s inclusion in the Nasdaq-100 has likely generated index-related buying and increased exposure among institutional investors, contributing to the recent rally. Moderna Stock Has Been on a Winning Streak
• Positive Sentiment: Health Canada is reviewing Moderna’s next-generation mRNA flu vaccine, which the company believes could reduce hospitalizations. Regulatory progress would expand Moderna’s commercial opportunities beyond COVID-19 vaccines. Health Canada Reviewing New mRNA Flu Vaccine
• Neutral Sentiment: Moderna will report third-quarter 2026 results and provide a corporate update on November 6. The report could offer important evidence about revenue trends, cash usage and progress toward its growth targets. Moderna to Report Third Quarter 2026 Financial Results
• Negative Sentiment: After the rapid advance, some investors appear to be reassessing whether Moderna’s oncology and vaccine prospects are already reflected in the share price. Profit-taking and concerns about the company’s continuing losses could increase volatility. Moderna Slides as Investors Reassess Near-Term Catalysts
• Negative Sentiment: Reported insider activity shows company executives selling shares without recorded open-market purchases during the past six months. In addition, several analyst price targets remain well below the current market valuation, highlighting skepticism about Moderna’s earnings outlook. MRNA Stock Gains Over $4B in a Week

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.